A number of other equities analysts have also recently issued reports on the stock. Morgan Stanley cut shares of Celgene from an equal weight rating to an underweight rating and set a $120.00 target price on the stock. in a report on Thursday, October 5th. Sanford C. Bernstein cut shares of Celgene from an outperform rating to a market perform rating and set a $121.00 target price on the stock. in a report on Wednesday, December 27th. BTIG Research restated a hold rating on shares of Celgene in a research note on Sunday, October 22nd. Cantor Fitzgerald restated a hold rating and issued a $112.00 price target on shares of Celgene in a research note on Monday, October 30th. Finally, Vetr upgraded shares of Celgene from a buy rating to a strong-buy rating and set a $144.39 price target on the stock in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, fourteen have given a hold rating and nineteen have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $131.18.
Shares of Celgene (NASDAQ CELG) traded up $1.42 during midday trading on Monday, reaching $106.00. 8,748,823 shares of the company’s stock were exchanged, compared to its average volume of 6,330,000. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17. The company has a market capitalization of $83,460.00, a PE ratio of 25.00, a P/E/G ratio of 0.68 and a beta of 1.77.
Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 30.06% and a return on equity of 43.32%. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter last year, the company posted $1.58 earnings per share. Celgene’s revenue was up 10.2% on a year-over-year basis. research analysts anticipate that Celgene will post 6.68 earnings per share for the current year.
Institutional investors have recently bought and sold shares of the stock. Capital Counsel LLC NY boosted its stake in shares of Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 6 shares during the period. Fort Pitt Capital Group LLC boosted its stake in shares of Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 11 shares during the period. Flagship Harbor Advisors LLC boosted its stake in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares during the period. Savant Capital LLC boosted its stake in shares of Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 20 shares during the period. Finally, TCI Wealth Advisors Inc. boosted its stake in shares of Celgene by 0.9% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 26 shares during the period. 79.74% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: “Celgene (CELG) Given a $127.00 Price Target at SunTrust Banks” was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://ledgergazette.com/2018/01/12/celgene-celg-given-a-127-00-price-target-at-suntrust-banks.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.